Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Showcase


Channel Catalog


Channel Description:

Visit One News Page for Australia news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Australia news headlines.

older | 1 | .... | 1434 | 1435 | (Page 1436) | 1437 | 1438 | .... | 1460 | newer

    0 0

    SINGAPORE, Dec. 20, 2018 /PRNewswire/ -- Frost & Sullivan honored Asia's leading companies at its 11^th annual Asia-Pacific Best Practices Awards banquet held on 27 November at the Shangri-La Hotel Singapore.

    Mr. Shivaji Das, Partner & Asia-Pacific Managing Director at Frost & Sullivan noted that the annual awards was held to honor and recognize companies that have pushed the boundaries of excellence in Asia-Pacific.

    "We are delighted to highlight best practices and honor companies that have delivered excellence in their respective industries. Through this recognition, Frost & Sullivan hopes that the companies will continue to excel and spur them to further achievements," he added.

    The recipients of the annual Frost & Sullivan Asia-Pacific Best Practices Awards were identified based on in-depth research conducted by Frost & Sullivan's analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.

    The nominated companies were then evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.

    Frost & Sullivan congratulates all the recipients of the 2018 Asia-Pacific Best Practices Awards.

    *GLOBAL*

    2018 Global Halal Glove Company of the Year

    KOSSAN RUBBER
    INDUSTRIES BHD

    2018 Global Medical Glove Technology Innovation Award

    SMART GLOVE HOLDINGS

    2018 Global API Manufacturing (Oligonucleotide) Growth
    Excellence Leadership Award

    ST PHARM

    2018 Global Integrated  Drug R & D Services Competitive
    Strategy Innovation & Leadership Award

    WUXI APPTEC

    *ASIA-PACIFIC*

    2018 Asia-Pacific OSS/BSS Vendor of the Year

    AMDOCS

    2018 Asia-Pacific Home Water Treatment Company of the
    Year

    AMWAY

    2018 Asia Pacific Outbound Systems Market Share
    Leadership Award

    ASPECT SOFTWARE (ASIA PACIFIC) PTE LTD

    2018 Asia-Pacific Contact Center Applications Growth Excellence
    Leadership Award

    ASPECT SOFTWARE (ASIA PACIFIC) PTE LTD

    2018 Asia-Pacific CRO Customer Value Leadership Award

    COVANCE INC

    2018 Asia Pacific Renewable Inverter Product Line Strategy
    Leadership Award

    DESTIN POWER INC

    2018 Asia-Pacific E-Commerce Logistics Service Provider of
    the Year

    DHL eCOMMERCE

    2018 Asia-Pacific Customer Experience System Integrator of
    the Year

    DIMENSION DATA ASIA PACIFIC

    2018 Asia-Pacific Demand-Side Management Growth
    Excellence Leadership Award

    GRIDWIZ, INC.

    2018 Asia Pacific Process Safety Systems Industry Growth
    Excellence Leadership Award

    HIMA

    2018 Asia-Pacific Self-Service Contact Centre Application
    Vendor of the Year

    HUAWEI

    2018 Asia-Pacific Telecom Equipment Vendor of the Year

    HUAWEI

    2018 Asia-Pacific AMI Solutions Company of the Year

    ITRON INC

    2018 Asia Pacific Secondary Battery Technology Innovation
    Award

    JENAX INC.

    2018 Asia Pacific Facilities Management Company of the
    Year

    JLL

    2018 Asia-Pacific Logistics Service Provider of the Year

    KERRY LOGISTICS
    NETWORK 

    2018 Asia-Pacific Road Transportation Service Provider of
    the Year

    KERRY LOGISTICS
    NETWORK 

    2018 Asia-Pacific Omni-Channel Logistics Service Provider
    of the Year

    LF LOGISTICS

    2018 Asia-Pacific Warehouse Service Provider of the Year

    LF LOGISTICS

    2018 Asia-Pacific Logistics Facilities Developer of the Year

    MAPLETREE LOGISTICS
    TRUST MANAGEMENT LTD

    2018 Asia-Pacific Clinical Trial IT Solutions Provider of the
    Year

    MEDIDATA SOLUTIONS

    2018 Asia-Pacific Biotech CRO Company of the Year

    NOVOTECH, THE ASIA
    PACIFIC CRO

    2018 Asia-Pacific Cloud Contact Center Service Provider of
    the Year 

    ORANGE BUSINESS
    SERVICES

    2018 Asia-Pacific Cloud UC Growth Excellence Leadership
    Award

    ORANGE BUSINESS
    SERVICES

    2018 Asia-Pacific Data Communication Service Provider
    of The Year

    ORANGE BUSINESS
    SERVICES

    2018 Asia-Pacific Data Center Infrastructure Service Provider
    of the Year

    SCHNEIDER ELECTRIC

    2018 Asia-Pacific UPS Competitive Strategy Innovation and
    Leadership Award

    SCHNEIDER ELECTRIC

    2018 Asia-Pacific Liquid Chromatograph - Mass Spectrometry New Product Innovation Award

    SHIMADZU

    2018 Asia Pacific Bottled Water Company of the Year

    SPRITZER

    2018 Asia-Pacific Property Development Competitive
    Strategy Innovation and Leadership Award

    SUNWAY BERHAD

    2018 Asia-Pacific Managed UC Services Provider of the Year

    TATA COMMUNICATIONS

    2018 Asia Pacific Smart Utility Communications Platform
    Company of the Year

    TRILLIANT HOLDINGS INC

    2018 Asia Pacific Customer Contact Optimization Solutions
    Vendor of the Year

    VERINT SYSTEMS

    *SOUTHEAST ASIA*

    2018 Southeast Asia Unified Communications System
    Integrator of the Year

    DIMENSION DATA ASIA PACIFIC

    2018 Southeast Asia Managed Security Service Provider
    of the Year

    TRUSTWAVE, A SINGTEL COMPANY

    *COUNTRY*

    2018 Australia Customer Contact Outsourcing Service
    Provider of the Year

    STELLAR

    2018 Australia Data Center Service Provider of the Year  

    EQUINIX

    2018 Cambodia Mobile Data Service Provider of the Year

    SMART AXIATA CO., LTD

    2018 Cambodia Mobile Service Provider of the Year

    SMART AXIATA CO., LTD

    2018 Indonesia Healthcare IT Company of the Year

    PT. QPRO SUKSES MANDIRI

    2018 Indonesia Smart City infrastructure Service Provider of
    the Year

    LINTASARTA

    Excellence in Customer Experience - Telecommunications
    Industry Indonesia - Overall Experience

    PT TELEKOMUNIKASI
    SELULAR

    Excellence in Customer Experience - Telecommunications
    Industry Indonesia -Online Experience

    PT TELEKOMUNIKASI
    SELULAR

    2018 Japan Managed Security Service Provider of the Year

    NRI SECURETECHNOLOGIES

    2018 North American Artificial Intelligence for Aging
    Research and Drug Development Technology Innovation
    Award

    INSILICO MEDICINE , INC. 

    2018 Philippines Contact Center System Integrator of the
    Year

    DTSI GROUP

    2018 Philippines Cloud Infrastructure Service Provider of the
    Year

    GLOBE TELECOM

    2018 Philippines Data Center Service Provider of the Year

    GLOBE TELECOM

    2018 Philippines Facilities Management Customer Value
    Leadership Award

    FPD ASIA PROPERTY
    SERVICES, INC.

    2018 Philippines Property Development Growth Excellence
    Leadership Award

    SM PRIME HOLDINGS, INC.

    2018 Singapore Data Center Competitive Strategy Innovation
    & Leadership Award

    SINGTEL

    2018 Singapore Managed Security Service Provider of the
    Year

    TRUSTWAVE, A SINGTEL
    COMPANY

    2018 Singapore Mobile Wallet Platform Growth Excellence
    Leadership Award

    MATCHMOVE PAY

    2018 Singapore Wholesale Colocation Data Center Service
    Provider of the Year

    KEPPEL DATA CENTRES

    2018 South Korea Managed Security Service Provider of the
    Year

    AHNLAB

    2018 Taiwan Data Center Service Provider of the Year

    CHUNGHWA TELECOM

    2018 Taiwan Mobile Service Provider of the Year

    CHUNGHWA TELECOM

    2018 Vietnam Hospital of the Year

    HOAN MY MEDICAL
    CORPORATION

    2018 China Contact Center Outsourcing Growth Excellence
    Leadership Award

    TELEPERFORMANCE CHINA

    *About Frost & Sullivan *

    Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?   Contact Us:     Start the discussion

    *Media Contact *

    Melissa Tan
    Corporate Communications – Asia-Pacific
    Phone: +65.6890.0926
    Email: melissa.tan@frost.com

     

    Related Links :

    http://www.frost.com Reported by PR Newswire Asia 13 minutes ago.

    0 0
  • 12/20/18--00:16: Change of Home Member State
  • THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

    *NB PRIVATE EQUITY PARTNERS: CHANGE OF HOME MEMBER STATE*

    20 December 2018

    Following the delisting of shares in NB Private Equity Partners Limited ("NBPE" or the "Company") from Euronext Amsterdam on 20 December 2018, the Board of the Company confirms that for the purposes of the Transparency Directive (Directive 2004/109/EC), as amended by the Transparency Directive Amending Directive (Directive 2013/50/EU), the Home Member State of NB Private Equity Partners Limited has changed from the Netherlands to the United Kingdom.

    *For further information, please contact:*

    *NBPE Investor Relations          +1 214 647 9593*
    *            *

    *Kaso Legg Communications    +44 (0)20 3137 7823*
    Charles Gorman                        nbpe@kl-communications.com

    *ABOUT NB PRIVATE EQUITY PARTNERS LIMITED*
    NBPE is a closed-end private equity investment company with class A ordinary shares admitted to trading on the Premium Segment of the Main Market of the London Stock Exchange. NBPE has 2022 and 2024 ZDP Shares admitted to trading on the Specialist Fund Segment of the Main Market of the London Stock Exchange. NBPE holds a diversified portfolio of direct equity investments, direct income investments and fund investments selected by the NB Alternatives group of Neuberger Berman, diversified across private equity asset class, geography, industry, vintage year, and sponsor.

    LEI number: 213800UJH93NH8IOFQ77

    *ABOUT NEUBERGER BERMAN*

    Neuberger Berman, founded in 1939, is a private, independent, employee-owned investment manager. The firm manages a range of strategies—including equity, fixed income, quantitative and multi-asset class, private equity and hedge funds—on behalf of institutions, advisors and individual investors globally. With offices in 20 countries, Neuberger Berman’s team is more than 2,000 professionals. For four consecutive years, the company has been named first or second in Pensions & Investments Best Places to Work in Money Management survey (among those with 1,000 employees or more). Tenured, stable and long-term in focus, the firm fosters an investment culture of fundamental research and independent thinking. It manages $315 billion in client assets as of September 30, 2018. For more information, please visit our website at www.nb.com.

    This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

    NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. NBPE is registered with the Dutch Authority for the Financial Markets as a collective investment scheme which may offer participations in The Netherlands pursuant to article 2:66 of the Financial Markets Supervision Act (Wet op het financial toezicht). All investments are subject to risk. Past performance is no guarantee of future returns. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE's investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains "forward-looking statements." Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements. Reported by GlobeNewswire 14 minutes ago.

    0 0

    Disgraced former Australia captain Steve Smith has tied up with the local arm of Britain's Vodafone Group in an advertising campaign that leverages the nation's ball-tampering shame for marketing purposes. Reported by DNA 14 minutes ago.

    0 0

    Steve Smith will speak to reporters at the SCG, marking his first public interview in Australia since returning in tears after the Cape Town cheating scandal. Reported by SBS 9 minutes ago.

    0 0

    Former Australia captain Allan Border defended Virat Kohli's aggression, saying cricket needs characters like the Indian skipper who exude passion on the field. Reported by DNA 4 minutes ago.

    0 0

    Rokt appealed the decision, challenging the refusal of the application. Reported by Mondaq 2 hours ago.

    0 0

    India's Adani Enterprises on Friday urged the government of Australia's Queensland state to approve a management plan that would allow construction to start at its controversial Carmichael coal mine. Reported by Reuters India 2 hours ago.

    0 0

    * Press Release*
    Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations
    *...............................................*

    *Encouraging preclinical efficacy data on NO-donating PDE5 inhibitors* *Focusing of research activities on the most promising new pharmacologic classes* *Collaboration with Novaliq to access novel formulation technology for these new compounds* *...............................................*

    December 21, 2018 - release at 7:30 am CET
    Sophia Antipolis, France

    *Nicox SA* (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it will be focusing its research activities on topical nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) stimulators.  As part of this focus, Nicox has entered into a research collaboration with *Novaliq GmbH * for the development of novel topical ophthalmic formulations of Nicox's NO-donating PDE5 inhibitors based on Novaliq's water-free enabling EyeSol^® technology, for lowering intraocular pressure (IOP).

    *Michele Garufi, Chairman and Chief Executive Officer of Nicox, said*, "We have been impressed by Novaliq's ability to successfully combine existing molecules and new chemical entities with their EyeSol^® technology.  It uses a novel class of excipient that offers an opportunity to create unique formulations for the development of our NO-donating PDE5 inhibitor new chemical entities as innovative intraocular pressure lowering drug candidates.  These novel formulations could potentially have multiple benefits, including improved ocular comfort and enhanced drug delivery performance with no antimicrobial preservative."

    "There are few new chemical entities in development for glaucoma patients, and the Nicox team is clearly at the forefront of the development of novel mechanisms of action for the lowering of intraocular pressure," *said Dr. Christian Roesky, Chief Executive Officer of Novaliq.*  "Our EyeSol^® technology has already successfully proved itself in multiple ophthalmic clinical studies and the partnership with Nicox allows us to bring together two novel technologies for innovation in the demanding field of glaucoma."

    In this collaboration, Novaliq is developing and characterizing novel formulations for lead series of the NO-donating PDE5 inhibitor new chemical entities using its EyeSol^® technology.  If successful, Nicox will be testing the novel topical ophthalmic formulations of NO-donating PDE5 inhibitors for IOP lowering activity in established pre-clinical models.  Newly developed intellectual property from the collaboration will be jointly owned. 

    * *

    *Focusing of Nicox Research*

     

    Nicox's research team has recently generated encouraging pre-clinical data that have compelled the Company to focus its research activities on the topical delivery of its future generation of NO-donors that combine NO-release with other mechanisms of action to potentially lower IOP.  These programs include the NO-donating PDE5 inhibitors, as well as the NO-donating sGC stimulators in partnership with Ironwood.  The Company intends to disclose some of the new data at key upcoming ophthalmology conferences in 2019.  As a result of this new focus, Nicox will discontinue its research collaboration with Re-Vana, as well as its work on stand-alone NO-donors.  Whilst the collaboration with Re-Vana met its objectives, the decision is strategic and not related to the quality of the Re-Vana technology, nor the professionalism of the Re-Vana Therapeutics team.

    As of January 1, 2019, Mike Bergamini, Ph.D., in a new role of Chief Scientific Advisor, will provide scientific advice to the Company as well as supporting Nicox's NO-donating research activities.

    * *

    *Future Generation NO-donors using sGC stimulation and PDE5 inhibition in the eye*

     

    We are actively researching NO-donating compounds of different chemical and pharmacological classes from those previously evaluated, both in-house and through our collaboration with Ironwood, in order to add NO donation to their existing mechanism of action (MOA) and thus potentially enhancing the IOP lowering and other desirable pharmaceutical properties of these classes of molecules.  Some of these are new therapeutic agent classes targeting conventional outflow through the trabecular meshwork by combining NO release with other pharmacological actions.  These new therapeutic agent classes include NO-donating sGC stimulators and NO-donating PDE5 inhibitors.  We expect to be able to announce a preclinical candidate from one of these programs in the next 18 months.

     

    NO is present in ocular tissues, together with other components involved in the NO signaling cascade via the activation of sGC.  The activation of sGC leads to the synthesis of cyclic guanosine monophosphate (cGMP) and an increase in the concentration of cGMP in the trabecular meshwork.  This increase is followed by the relaxation of the trabecular meshwork and increased outflow of the aqueous humor from the anterior segment of the eye through the conventional outflow pathway.  All of the foregoing lead to IOP lowering.  The effect of NO in the sGC signaling cascade can be further increased or prolonged by sGC stimulators and/or by PDE5 inhibitors.

     

    sGC stimulators and NO interact synergistically on sGC which result in greater cGMP production, as compared to the cGMP production that results from exposure to either sGC stimulators or NO alone.  Further, PDE5 inhibitors inhibit phosphodiesterase type 5, a key enzyme that degrades cGMP to inactive guanosine monophosphate (GMP).  This inhibition of PDE5 prevents the conversion of cGMP to inactive GMP which prolongs the duration of action of cGMP on the trabecular meshwork following the activation of sGC by NO.

     

    *About EyeSol^®*

     

    As the first water-free enabling technology for ophthalmology products, EyeSol^® enhances traditionally water-insoluble drugs.  EyeSol^® is based on specific semi-fluorinated alkanes (SFAs).  These compounds have the same refractive index as water and are transparent, inert, non-toxic, amphiphilic liquids that can formulate lipophilic and large molecules.  Due to their low surface tension and viscosity, SFAs dispense as a low volume drop that does not stimulate blinking or reflex tearing.  

    Being water-free, EyeSol^® products avoid oxidative reactions that might degrade active pharmaceutical ingredients, thus improving product stability.  In addition, the water-free EyeSol^® technology does not permit microbial growth, and therefore it allows manufacturing of antimicrobial preservative-free formulations in multi-dose containers.

    * *

    *About Novaliq*

     

    Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol^®, the worldwide first water-free technology for ophthalmology.  With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today's unmet medical needs of millions of patients with eye diseases: Novaliq's lead assets in late-stage clinical development are CyclASol^® and NOV03: CyclASol^® is an anti-inflammatory and immune-modulating drug for the treatment of DED with a demonstrated early onset of action and an excellent tolerability. NOV03 is the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD). NovaTears^® water-free eye drops for dry eye have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.

    Novaliq is headquartered in Heidelberg, Germany and has also an office in Cambridge, MA, USA.  The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.  More on Novaliq at www.novaliq.com.

     
    *About Nicox*
    Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma.  Our portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis.  Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).  In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA^® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE(TM) (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyevance Pharmaceuticals.  

    Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

    For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
    *Analyst coverage*
    Bryan, Garnier & Co   Hugo Solvet    Paris, France
    Invest Securities   Martial Descoutures    Paris, France

       
     

    The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
    *Upcoming financial and business conferences*
     

    January 22, 2019  Invest Securities BioMed Event   Paris, France
    February 12, 2019  European Midcap Event   Frankfurt, Germany
    March 19-20, 2019  Oppenheimer's 29th Annual healthcare Conference  New York, U.S. 
    April 7-9, 2019  H.C. Wainwright Global Life Sciences Conference   London, UK
    *Contacts*
    *Nicox*
    Gavin Spencer,
    Executive Vice President, Chief Business Officer
    T +33 (0)4 97 24 53 00
    communications@nicox.com
    Investors & media
    United States & Europe
    LifeSci Advisors, LLC
    Hans HerklotsT +41 79 598 71 49  
    hherklots@lifesciadvisors.com Media
    Italy
    Argon Healthcare International
    Pietro Pierangeli
    pietro.pierangeli@argonhealthcare.com 
    Chiara Tettamanti
    chiara.tettamanti@argonhealthcare.com 
    T +39 02 4951.8300
    Media
    France
    LifeSci Advisors, LLC
    Sophie Baumont
    M. +33 (0)6 27 74 74 49
    sophie@lifesciadvisors.com

    * *

    * *

    * *  
    *Disclaimer*
    The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

    Risks factors which are likely to have a material effect on Nicox's business are presented in the 4^th chapter of the 'Document de référence, rapport financier annuel et rapport de gestion 2017' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018 which is available on Nicox's website (www.nicox.com).
    *Nicox S.A.*
    Drakkar 2
    Bât D, 2405 route des Dolines
    CS 10313, Sophia Antipolis
    06560 Valbonne, France
    T +33 (0)4 97 24 53 00
    F +33 (0)4 97 24 53 99

    *Attachment*

    · Press release.pdf Reported by GlobeNewswire 2 hours ago.

    0 0

    Most cricket nations have avoided touring Pakistan since 2009 when gunmen attacked a bus carrying Sri Lankan cricketers, injuring six players and killing six security personnel and two civilians. Reported by SBS 2 hours ago.

    0 0

    SYDNEY - Researchers in Australia say that fact checking can reverse the views of even the most dyed-in-the-wool partisans, and over time could cause voters to shun an often-lying candidate. Reported by Bangkok Post 2 hours ago.

    0 0

    MELBOURNE, Australia (AP) — Banned former Australia cricket captain Steve Smith says he hopes to be part of the country's World Cup and Ashes teams in England this summer and that he expects a hostile reaction from English spectators.Smith... Reported by New Zealand Herald 2 hours ago.

    0 0

    Angle PLC Announces Issue of LTIP Options and Share Options * GUILDFORD, SURREY / ACCESSWIRE / December 21, 2018 / *ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, announces that, at the recommendation of certain of its major shareholders, it has established a Long-Term Incentive Plan ("LTIP") under the Remuneration Policy approved by the shareholders at the Annual General Meeting on 30 October 2018.

    The Remuneration Committee has approved the grant under the LTIP of options (the "LTIP Options") over a maximum of 6,000,000 ordinary shares of £0.10 ("Ordinary Shares"), dependent on certain strict performance conditions, to the Company's executive directors. Separately the Remuneration Committee has also approved the issue of up to 4,000,000 share options under its existing share option plans to certain staff (the "Staff Share Options").

    Following the issue of these options, the Company will have outstanding options over a total of up to 20,555,806 Ordinary Shares, representing approximately 12% of its issued and to be issued share capital, which is within the approved limit of up to 16%.

    The exercise price for the Staff Share Options is 38.5 pence per Ordinary Share, representing the Company's closing mid-market share price on 20 December 2018, being the latest practicable date prior to this announcement. The Staff Share Options are subject to certain service and/or performance conditions over a three year period.

    The LTIP Options have performance conditions as set out below, a performance period of three years and an additional holding period of two years. Subject to the rules of the LTIP, awards will vest only to the extent that the performance conditions have been met at the end of the performance period and the underlying shares may only be traded once the holding period is completed. The LTIP Options contain normal "good leaver", "bad leaver" and change of control provisions, and malus and clawback provisions will apply under certain circumstances.

    The intention of the LTIP is to reward tangible increases in shareholder value. The performance conditions for the LTIP Options relate to the compound annual growth rate (CAGR) of the share price over the three year performance period. As different levels of performance are achieved the number of shares that vest increases up to a maximum as set out below:
    Allocation of LTIP options

    Share price CAGR

    Multiple of share price

    Proportion vesting

    Andrew Newland

    Ian Griffiths

    Total



    0%







    > 40%

    > 2.7

    20%

    720,000

    480,000

    1,200,000

    > 55%

    > 3.7

    50%

    1,800,000

    1,200,000

    3,000,000

    > 75%

    > 5.4

    100%

    3,600,000

    2,400,000

    6,000,000




    The non-executive directors of the Company do not hold share options.

    As at 20 December 2018, the Company has 143,486,522 Ordinary Shares in issue.

    *The below notification made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.*

    *1*

    *Details of the person discharging managerial responsibilities / person closely associated*

    a)

    Name

    Andrew Newland

    *2*

    *Reason for the notification*

    a)

    Position/status

    Chief Executive Officer

    b)

    * *

    Initial notification /Amendment

    Initial notification

    *3*

    *Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor*

    a)

    Name

    ANGLE plc

    b)

    * *

    LEI

    213800BY11K6W3NMS374

    *4*

    *Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted*

    a)

    Description of the financial instrument, type of instrument

    Identification code

    Options over Ordinary shares of 10p each

    ISIN: GB0034330679

    b)

    * *

    Nature of the transaction

    Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme

    c)

    Price(s) and volume(s)

    Price(s)

    Volume(s)

    Nil

    Up to 3,600,000 dependent on performance

    d)

    Aggregated information

    - Aggregated volume

    - Price

    N/A

    e)

    Date of the transaction

    21 December 2018

    f)

    Place of the transaction

    Outside a trading venue

    *1*

    *Details of the person discharging managerial responsibilities / person closely associated*

    a)

    Name

    Ian Griffiths

    *2*

    *Reason for the notification*

    a)

    Position/status

    Finance Director

    b)

    * *

    Initial notification /Amendment

    Initial notification

    *3*

    *Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor*

    a)

    Name

    ANGLE plc

    b)

    * *

    LEI

    213800BY11K6W3NMS374

    *4*

    *Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted*

    a)

    Description of the financial instrument, type of instrument

    Identification code

    Options over Ordinary shares of 10p each

    ISIN: GB0034330679

    b)

    * *

    Nature of the transaction

    Grant of nil-cost LTIP options over ordinary shares under the ANGLE plc LTIP Scheme

    c)

    Price(s) and volume(s)

    Price(s)

    Volume(s)

    Nil

    Up to 2,400,000 dependent on performance

    d)

    Aggregated information

    - Aggregated volume

    - Price

    N/A

    e)

    Date of the transaction

    21 December 2018

    f)

    Place of the transaction

    Outside a trading venue

    *For further information ANGLE:*

    *ANGLE plc*

    *+44 (0) 1483 343434*

    Andrew Newland, Chief Executive

    Ian Griffiths, Finance Director



    *finnCap Ltd (NOMAD and Joint Broker)*

    Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

    ECM - Alice Lane

    * *

    *+44 (0)20 7220 0500*

    *WG Partners (Joint Broker)*

    Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

    * *

    *+44 (0) 203 705 9330*

    * *

    *FTI Consulting*

    Simon Conway, Mo Noonan, Stephanie Cuthbert

    Matthew Ventimiglia (US)

    * *

    *+44 (0) 203 727 1000*

    *+1 212 850 5612*

    For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

    This announcement contains inside information.

    *Notes for editors*

    *About ANGLE plc * www.angleplc.com

    ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

    ANGLE's cell separation technology is called the Parsortix ^TM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States.

    ANGLE's analysis technology for proteins and nucleic acids of all types is called the Ziplex^® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests.

    ANGLE's proprietary technologies can be combined to provide automated, sample to answer results in both centralised laboratory and point -of-use cartridge formats.

    Furthermore, ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/

    This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

    *SOURCE:* ANGLE plc*
    *
    View source version on accesswire.com:
    https://www.accesswire.com/531204/Angle-PLC-Announces-Issue-of-LTIP-Options-and-Share-Options Reported by Accesswire 2 hours ago.

    0 0

    *Falcon Oil & Gas Ltd. (“Falcon”)**AIM and ESM Admission*

    21 December 2018 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG, ESM: FAC) announces that an application has been made to AIM and ESM for the admission to trading of 1,100,000 previously issued common shares of no par value, in Falcon. Admission is expected to occur on 24 December 2018.  The common shares were issued pursuant to the exercise of options granted under Falcon’s approved stock option plan.

    *CONTACT DETAILS*:

    *Falcon Oil & Gas Ltd.   * +353 1 676 8702
    Philip O'Quigley, CEO +353 87 814 7042
    Anne Flynn, CFO +353 1 676 9162
       
    *Davy (NOMAD & Joint Broker) *  
    John Frain / Barry Murphy +353 1 679 6363
       
    *RBC (Joint Broker)*  
    Matthew Coakes / Martin Copeland  +44 20 7653 4000
       
    *Cenkos Securities plc (Joint Broker)*  
    Neil McDonald / Derrick Lee +44 131 220 9771

    *About Falcon Oil & Gas Ltd.*
    Falcon Oil & Gas Ltd is an international oil and gas company engaged in the acquisition, exploration and development of conventional and unconventional oil and gas assets, with the current portfolio focused in Australia, South Africa and Hungary. Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland with a technical team based in Budapest, Hungary.

    For further information on Falcon Oil & Gas Ltd. please visit www.falconoilandgas.com

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Reported by GlobeNewswire 2 hours ago.

    0 0

    The Pakistan Cricket Board is hopeful of convincing Cricket Australia that at least some part of an upcoming ODI series should be played in Pakistan. Reported by SBS 1 hour ago.

    0 0

    Reported by RIA Nov. 1 hour ago.

    0 0

    Former Australia captain Steve Smith said he is desperate to recover lost ground ahead of next year's World Cup by competing in the IPL after being left so deflated by the ball-tampering scandal that getting out of bed became a struggle. Reported by Rediff.com 1 hour ago.

    0 0

    Australia's largest city is picking up the pieces after a series of lightning and hailstorms pummelled cars with ice blocks the size of tennis balls. Reported by News24 49 minutes ago.

    0 0

    A former Manus Island detainee, who sought refuge in Australia, will take his fight to the boxing ring in a bid to help refugees on Manus Island and Nauru. Reported by SBS 46 minutes ago.

    0 0

    A warm and dry Christmas Day is on the way aside from a few areas in the northern tropics where rain has been predicted. Reported by SBS 46 minutes ago.

    0 0

    Stoinis failed to make it to the 13-member Australian Test squad despite notching up scores of 10, 81, 21 and 85 in two JLT Sheffield Shield games this season.  Reported by Zee News 40 minutes ago.

older | 1 | .... | 1434 | 1435 | (Page 1436) | 1437 | 1438 | .... | 1460 | newer